Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells. Read more about Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells.
Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer. Read more about Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer.
Ovariectomy shortens the life span of female mice. Read more about Ovariectomy shortens the life span of female mice.
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Read more about Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Read more about Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. Read more about Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence. Read more about YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence.
Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Read more about Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.
Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Read more about Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Read more about Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
